$INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues

Home » Company Interviews » $INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues

In this episode of the CEOLIVE.TV Investor Profile Series we interview Dr. Bassam Damaj, CEO of Innovus Pharmaceuticals.

Dr. Damaj discusses recent acquisitions, the company’s strong commercial pipeline and why Innovus Pharmaceuticals (INNV) is undervalued right now.

About Innovus Pharmaceuticals

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Disclosure: Neither CEOLIVE.TV or any of its principals currently owns or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer.

Get Alerts for Latest Featured Stocks!
Signup today and receive the newest videos. We will never share or sell your email address.
Author: Mike Elliott

Login

Lost your password?